News
ICLR
300.92
-0.51%
-1.53
ICON draws bullish view at Leerink on business model
Seeking Alpha · 1d ago
Icon Price Target Announced at $379.00/Share by Leerink Partners
Dow Jones · 1d ago
Icon Initiated at Outperform by Leerink Partners
Dow Jones · 1d ago
Leerink Partners Initiates Coverage On Icon with Outperform Rating, Announces Price Target of $379
Benzinga · 1d ago
Icon’s Market Leadership and Financial Fortitude Warrant a Strong Buy Rating
TipRanks · 1d ago
Weekly Report: what happened at ICLR last week (0909-0913)?
Weekly Report · 3d ago
Implied Volatility Surging for ICON (ICLR) Stock Options
NASDAQ · 6d ago
Icon PLC (ICLR) Surges 3.3%: Is This an Indication of Further Gains?
NASDAQ · 09/12 08:37
ICON Survey Highlights Scale of Focus on Precision Therapies in Increasingly Complex Oncology Landscape
Barchart · 09/12 06:15
ICON shares rebound as analysts say selloff is overdone
Seeking Alpha · 09/11 18:51
Icon Price Target Maintained With a $383.00/Share by Truist Securities
Dow Jones · 09/11 16:14
Icon Price Target Maintained With a $368.00/Share by Baird
Dow Jones · 09/11 16:09
Icon Is Maintained at Outperform by Baird
Dow Jones · 09/11 16:09
Truist Securities Reiterates Buy on Icon, Maintains $383 Price Target
Benzinga · 09/11 16:04
Baird Maintains Outperform on Icon, Maintains $368 Price Target
Benzinga · 09/11 15:59
Truist Financial Keeps Their Buy Rating on Icon (ICLR)
TipRanks · 09/11 11:08
Maintaining Buy Rating on Icon Stock Amid Unwarranted Selloff and Strong Growth Prospects
TipRanks · 09/11 11:06
Should You Think About Buying ICON Public Limited Company (NASDAQ:ICLR) Now?
Simply Wall St · 09/09 15:42
Weekly Report: what happened at ICLR last week (0902-0906)?
Weekly Report · 09/09 09:19
Here's How Much $100 Invested In Icon 20 Years Ago Would Be Worth Today
Benzinga · 09/04 20:00
More
Webull provides a variety of real-time ICLR stock news. You can receive the latest news about ICON PLC through multiple platforms. This information may help you make smarter investment decisions.
About ICLR
ICON Public Limited Company is a healthcare intelligence and clinical research organization. The Company is engaged in providing outsourced services to pharmaceutical, biotechnology, medical device and government and public health organizations. It offers a range of specialized services to assist pharmaceutical, biotechnology and medical device companies to bring new drugs and devices to market faster. The Company's services include clinical research services, commercial positioning, consulting, early phase, strategic solutions, laboratories, language services, medical imaging, real world intelligence, site and patient solutions, COVID-19 clinical operation and decentralized and hybrid clinical solutions. It also provides its full range of clinical, consulting and commercial services across several sectors, which include biosimilars, biotechnology, government and public health solutions, medical devices and pharmaceuticals.